Are you a Health Professional? Jump over to the doctors only platform. Click Here

SinoFresh to Collaborate with Lovelace Respiratory Research Institute

Print Friendly, PDF & Email

SinoFresh HealthCare, Inc. (OTC BB: SFSH) developer of the first over-the-counter nasal spray, SinoFresh(TM) Antiseptic Nasal and Sinus Care, proven to kill germs and molds associated with chronic sinus and nasal conditions, today announced it has entered into a Research and Development Agreement with the Lovelace Respiratory Research Institute of Albuquerque, New Mexico.

SinoFresh HealthCare, Inc. (OTC BB: SFSH) developer of the first over-the-counter nasal spray, SinoFresh(TM) Antiseptic Nasal and Sinus Care, proven to kill germs and molds associated with chronic sinus and nasal conditions, today announced it has entered into a Research and Development Agreement with the Lovelace Respiratory Research Institute of Albuquerque, New Mexico. The effort is focused on joint-sponsored programs designed to find new therapeutic uses for SinoFresh’s popular antiseptic nasal spray product in the respiratory arena. Initial emphasis will center on possible anti-infective applications of the product. Specifically, the collaboration hopes to prove efficacy in the protection against various strains of virus of concern to bio-defense. “We are very excited to be working in concert with such a renowned research institute,” said P. Robert DuPont, Vice President of Research and Development of SinoFresh. DuPont added, “SinoFresh is hopeful that this collaboration will reveal further potential applications for our broad-spectrum antiseptic therapy.” Founded in 1947 as a private, not-for-profit corporation, the Lovelace Respiratory Research Institute occupies 450,000 square feet of facilities and employs 50 PhD level scientists, and 270 technicians and support staff. About SinoFresh HealthCare, Inc. SinoFresh HealthCare, Inc. is the developer of the first over-the-counter antiseptic nasal spray proven to kill germs and reduce molds responsible for chronic sinus distress. This condition affects more than 37 million Americans every day. The company holds several patents on its innovative pharmaceutical technology, and is involved in the research and development of many forms of chronic respiratory disorders. SinoFresh relies upon a distinguished panel of medical experts and a management team experienced in the bio-pharmaceutical arena. More information is available at www.sinofresh.com. About The Lovelace Respiratory Research Institute The Lovelace Respiratory Research Institute is a private biomedical research institute dedicated to the reduction of the nation’s substantial respiratory health burden. The Institute brings a broad range of research capabilities and research alliances to bear on respiratory health issues of concern to government, industry, universities, health advocacy organizations, and the public. Lovelace is committed to the cure of respiratory diseases through research aimed at understanding their causes and biological mechanisms, eliminating exposures to causal agents, and developing improved treatments. With its diverse research capabilities, its close working relationships with universities and other laboratories, and its endowed and sponsored research programs, the Lovelace Respiratory Research Institute is one of the nation’s largest independent, non-profit biomedical research institutions, and the nation’s only such organization wholly dedicated to basic research on respiratory health problems. More information is available at www.lrri.org. Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements speak only as of the date on which such statements are made and involve risks and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission, including risks summarized in the Company’s Annual Report on Form 10-KSB for its fiscal year ended December 31, 2003 (file No. 0-49764). The Company’s actual results could differ materially from such forward-looking statements. The Company undertakes no obligation to update any forward-looking statement or statements to reflect new events or circumstances or future developments. (Source: Buisness Wire Health News, May 2004)

Print Friendly, PDF & Email

Dates

Posted On: 6 May, 2004
Modified On: 5 December, 2013

Tags



Created by: myVMC